Penn Medicine Provider
Medical Oncology
Saya L. Jacob, MD
4.8
(44)
Accepting new patients
Sees patients age 18 and up
Rena Rowan Breast Center

About me

  • Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: Northwestern University Feinberg School of Medicine
  • Residency: Northwestern Memorial Hospital
  • Fellowship: UCSF Medical Center and Hospital

What my patients think about me

Average Rating
4.8

44 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

June 2025
5.0
5.0
knowledgeable and caring
June 2025
5.0
5.0
patience
May 2025
5.0
5.0
very helpful
April 2025
5.0
5.0
knowledgeable, caring attitude, presented various treatment options, asked about how stage 4 cancer impacts my daily activities, what my goals were, she read through the epic notes from fox chase before my appointment

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Jacob is a Penn Medicine physician.

Qualifications and experience

My research

Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy , Breast Cancer Res Treat: 2024


Zhang Q, Cai Z, Gerratana L, Davis AA, D'Amico P, Chawla A, Jacob S, Zhang Y, Jiao J, Qin W, Reduzzi C, Flaum L, Shah A, Gradishar WJ. Early Evaluation of Risk Stratification and Clinical Outcomes for Patients with Advanced Breast Cancer through Combined Monitoring of Baseline Circulating Tumor Cells and DNA. , Clin Cancer Res: 2024


Jacob S, Johnson M, Roque B, Quintal L, Rugo HS, Melisko M, and Chien AJ. “Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.” , Clin Breast Cancer , 23(7): 2023,721-728


Saya Jacob, Edward Maldando, Meera Ragavan, Vanessa Kennedy, Rahul Banerjee, Amy Lin, Ana Velazquez. Development of Implementation of a Fertility Preservation Order Set In Comprehensive Cancer Center: A Quality and Equity Initiative. , American Society of Clinical Oncology Quality Symposium, Boston, MA.: 2023


Gerratana L, Reduzzi C, D'Amico P, Mazzeo R, Jacob S, Qiang W, Cristofanilli M. Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer. , Current Cancer Research : 2023,10.1007/978-3-031-22903-9_21.


Jacob S, Johnson M, Roque B, Quintal L, Rugo HS, Melisko M, Chien AJ. Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer. , Clin Breast Cancer: 2023


Saya Jacob, Zoe Quandt, Michelle Melisko, Melanie Majure, Amy Jo Chien, Anne Blaes, Diane Heditsian, Laura Esserman, Hope Rugo. Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors. , American Society of Clinical Oncology Annual Meeting, Chicago, IL. : 2023


Zhang Q, DavisA, Gerratana L, D'Amico P, Reduzzi C, Qin W, Jiao J, Qiang Wenan, Jacob S, Chawla A, Flaum L, Shah, A, Cristofanilli Massimo, Gradishar W. Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC). , American Society of Clinical Oncology Annual Meeting, Chicago, IL.: 2023


Saya Jacob, Adil Daud. Phase Ib/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease. , American Society of Clinical Oncology Annual Meeting, Chicago, IL.: 2023


Saya Jacob, Hongmei Yu, Denise M. Wolf, Aheli Chattopadhyay, Susie Brain, Carol Simmons, Kathryn Jean Ruddy, Irene Kang, Anne Hudson Blaes, Amrita B Somani, Dawn L. Hershman, Laura Esserman, Michelle E. Melisko. Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2. , American Society of Clinical Oncology Annual Meeting, Chicago, IL. : 2023